CoChat
Sign Up
Cited by 112Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesCriminal Justice and Corrections Analysis

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

A randomized controlled trial of prison-initiated buprenorphine: Prison outcomes and community treatment entry

Open access
Gordon, Michael S., Kinlock, Timothy W., Schwartz, Robert P., Fitzgerald, Terrence T., O’Grady, Kevin E., Vocci, Frank J.·2014·Drug and Alcohol Dependence
DOI 10.1016/j.drugalcdep.2014.05.011PMC PMC4129444
Open this paper in CoChat — free account

Abstract

Background Buprenorphine is a promising treatment for heroin addiction. However, little is known regarding its provision to pre-release prisoners with heroin dependence histories who were not opioid-tolerant, the relative effectiveness of the post-release setting in which it is provided, and gender differences in treatment outcome in this population.Methods This is the first randomized clinical trial of prison-initiated buprenorphine provided to male and female inmates in the US who were previously heroin-dependent prior to incarceration. A total of 211 participants with 3-9 months remaining in prison were randomized to one of four conditions formed by crossing In-Prison Treatment Condition (received buprenorphine vs. counseling only) and Post-release Service Setting (at an opioid treatment center vs. a community health center). Outcome measures were: entered prison treatment; completed prison treatment; and entered community treatment 10 days post-release.Results There was a significant main effect (p=.006) for entering prison treatment favoring the In-Prison buprenorphine Treatment Condition (99.0% vs. 80.4%). Regarding completing prison treatment, the only significant effect was Gender, with women significantly (p<.001) more likely to complete than men (85.7% vs. 52.7%). There was a significant main effect (p=.012) for community treatment entry, favoring the In-Prison buprenorphine Treatment Condition (47.5% vs. 33.7%).Conclusions Buprenorphine appears feasible and acceptable to prisoners who were not opioid-tolerant and can facilitate community treatment entry. However, concerns remain with in-prison treatment termination due to attempted diversion of medication.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.drugalcdep.2014.05.011

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 112

Related

See all

Metadata

Authors
Gordon, M. S., Kinlock, T. W., Schwartz, R. P., Fitzgerald, T. T., O’Grady, K. E., & Vocci, F. J.
Affiliations
  • Stevenson University (US)
  • Friends Research Institute (US)
  • University of Maryland, Baltimore (US)
  • University of Maryland, College Park (US)
Corresponding author
Gordon, Michael S.
ORCID
Venue
Drug and Alcohol Dependence
Publisher
Elsevier BV
Published
2014-09
Volume
142
Pages
33-40
ISSN
0376-8716 (ISSN-L)
DOI
10.1016/j.drugalcdep.2014.05.011
PMC
PMC4129444
OpenAlex
W1979097541
Cited by
112
References
46
Citations by year
2026: 3 · 2025: 6 · 2024: 12 · 2023: 12 · 2022: 10 · 2021: 12 · 2020: 9 · 2019: 13 · 2018: 8 · 2017: 5 · 2016: 11 · 2015: 9 · 2014: 1
FWCI
8.59
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Drug and Alcohol Dependence (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute on Drug Abuse (R01DA021579)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Social Sciences › Sociology and Political Science › Criminal Justice and Corrections Analysis
Keywords
buprenorphine, heroin addiction, opioid use disorder, opioid-tolerant patients, community-based treatment, gender differences, treatment completion, drug diversion
MeSH terms
Adult, Buprenorphine, Combined Modality Therapy, Counseling, Female, Heroin Dependence, Humans, Male, Middle Aged, Narcotics, Prisoners, Prisons, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review